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Purpose: Testing for inborn errors of metabolism is performed by
clinical laboratories worldwide, each utilizing laboratory-developed
procedures. We sought to summarize performance in the College of
American Pathologists’ (CAP) proficiency testing (PT) program
and identify opportunities for improving laboratory quality. When
evaluating PT data, we focused on a subset of laboratories that have
participated in at least one survey since 2010.
Methods: An analysis of laboratory performance (2004 to 2014) on
the Biochemical Genetics PT Surveys, a program administered by
CAP and the American College of Medical Genetics and Genomics.
Analytical and interpretive performance was evaluated for four tests:
amino acids, organic acids, acylcarnitines, and mucopolysaccharides.
Results: Since 2010, 150 laboratories have participated in at least one
of four PT surveys. Analytic sensitivities ranged from 88.2 to 93.4%,
while clinical sensitivities ranged from 82.4 to 91.0%. Performance
was higher for US participants and for more recent challenges.
Performance was lower for challenges with subtle findings or complex
analytical patterns.
Conclusion: US clinical biochemical genetics laboratory proficiency
is satisfactory, with a minority of laboratories accounting for the
majority of errors. Our findings underscore the complex nature of
clinical biochemical genetics testing and highlight the necessity of
continuous quality management.
Genet Med advance online publication 29 June 2017
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INTRODUCTION
Clinical biochemical genetics is a medical specialty devoted to
diagnosing and treating inborn errors of metabolism (IEMs).
IEMs encompass a heterogeneous group of genetic conditions
including disorders of amino acid (AA; e.g., phenylketonuria),
organic acid (OA; e.g., methylmalonic aciduria, MMA),
mucopolysaccharide (MPS; e.g., Hurler syndrome), and fatty
acid metabolism (e.g., medium-chain acyl-CoA dehydrogen-
ase, MCAD, deficiency). Although individually rare, their
estimated combined incidence is as high as 1:800–1:2,500
births.1,2 Symptoms often appear early in life, but clinical
outcomes are optimized by an early diagnosis and therapy
instigation before irreversible damage has occurred.3
An IEM diagnosis is established through high-complexity,
laboratory-developed tests performed by a relatively small
number of laboratories worldwide, called clinical biochemical
genetics laboratories (BGLs). Methods vary between labora-
tories, but they typically include high-pressure liquid
chromatography, gas chromatography/mass spectrometry
and/or liquid chromatography–tandem mass spectrometry
(LC-MS/MS). There are no US Food and Drug Administra-
tion–cleared tests for biochemical genetics testing, a
commonality shared with molecular genetics labo-
ratories and DNA-based testing for rare heritable conditions.
Despite the nonstandardized nature of laboratory testing,
molecular genetic testing quality is very high.4–11 Never-
theless, biochemical genetic testing poses unique challenges to
the clinical laboratory, including the innate task of assessing
multiple analytes in a single test, and the inter- and
intrapatient metabolic variability due to genotype, clinical
status, or other intrinsic and extrinsic factors. Thus, it is vital
that laboratories perform extensive validation and ongoing
test monitoring to ensure the highest quality for patient care.
Participation in proficiency testing (PT) is associated with
improved laboratory quality, particularly in the laboratory-
developed test setting.12–14 External PT schemes for BGL
testing were first introduced in the United States in the 1980s,
with a review of outcomes highlighting the importance
of ongoing training, education, and quality oversight in
the area of IEM diagnosis.15,16 Comprehensive PT is also
offered by the European Research Network for Evaluation and
Improvement of Screening, Diagnosis and Treatment of
Inherited Disorders of Metabolism (ERNDIM), which
reported a positive correlation between participation and
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laboratory quality.17 In 1993, the College of American
Pathologists (CAP), in collaboration with the American
College of American Genetics and Genomics (ACMG),
introduced a BGL PT program that included the analysis of
AAs, OAs, and MPS. The program was expanded in 2004 to
include plasma acylcarnitine (AC) performance.
Here, we present an analysis of the CAP/ACMG Bio-
chemical Genetics Resource Committee PT program from
more than 10 years of surveys (2004 through 2014). The
analysis was restricted to laboratories that had participated in
at least one PT survey since 2010. This was done to allow
for estimates of recent laboratory performance, but it also
permitted the examination of earlier PT performance in a
subset of active laboratories.
MATERIALS AND METHODS
BGL proficiency testing survey
The PT survey consists of five specimens distributed twice
yearly (an A and B distribution) to laboratories in the United
States and abroad. Each mailing contained one specimen for
every analysis, including plasma or urine AA, urine OA,
plasma AC, and urine MPS. A fifth specimen, excluded from
this analysis, is an ungraded educational challenge focusing
on less frequently encountered areas of AA, OA, or AC
testing. This report includes results from 21 BGL surveys from
the 2004-B through 2014-B mailings.
Most specimens were authentic plasma or urine samples
from patients with clinically confirmed diagnoses. Occasionally,
samples were from unaffected individuals, pooled samples, or
spiked with one or more compounds to mimic a metabolic
disorder. All plasma samples used had negative test results for
hepatitis B surface antigen, hepatitis C antibody, and HIV
antigen/antibody. Challenges were pretested by multiple
reference laboratories to verify suitability. Specimens were
stored at − 20 °C or lower, and aliquots were shipped on dry
ice. A clinical history accompanied each challenge. Participants
reported all diagnostically relevant analyte(s), the most likely
diagnosis (clinical interpretation) based on analytic results and
clinical history, and by selecting answers from a predefined list.
Information about testing methodology and results of analyte
quantitation were requested but not required or graded.
Laboratories returned results within 30 days via an online
result submission form or facsimile.
Data collection and analysis
Data were extracted from the CAP data management system
and de-identified. These data encompassed participant results,
including those returned after the required submission date
and excluded from original Participant Summary Reports.
Each challenge’s analytic and interpretative results were
graded as “Acceptable” or “Unacceptable” based on partici-
pant consensus (>80%) or, in a few instances, on the
consensus of reference laboratory results. Missing analytic
results or missing clinical interpretations were not graded and
were excluded from analysis. Members of the CAP/ACMG
Biochemical and Molecular Genetics Resource Committee
reviewed results and approved grading criteria. Acceptable
results were based on either the identification of a well-
recognized, analytical profile, or a pathognomonic analyte
level, depending on the circulated specimen, and correlation
with the provided clinical scenario. A two-dimensional matrix
of the graded responses stratified by time (columns) and
participants (rows) was created. These “heat maps” were used
to compute analytic sensitivity (the proportion of abnormal
analytes correctly identified) and clinical sensitivity (the
proportion of disorders correctly diagnosed) for all challenges.
Calculations of clinical sensitivity included separate analyses
for two types of false-negative results. One type occurs when
participants recognize a specimen as having an abnormal
clinical interpretation but report the incorrect disorder (i.e., not
the intended response). The second type occurs when
participants fail to recognize any clinical disorder and interpret
the result as “Normal, unaffected.” This latter type is the classic
false negative. The MPS survey had multiple challenges from
unaffected individuals (six in total) and these were used to
calculate analytic specificity (the proportion of normal speci-
mens with no abnormal analytes reported) and clinical
specificity (the proportion of normal specimens correctly
diagnosed as normal). Rates were compared using the chi-
squared test with a two-tailed significance level of 0.05. The
95% confidence intervals for proportions were computed using
the adjusted Wald asymptotic method.
RESULTS
Participants and tests challenged
A total of 150 laboratories participated in the program for at
least one of the AA, OA, AC, and MPS challenges since 2010,
including 97 US and 53 international laboratories (North
America, South America, Asia, and Europe). Of these, 35
(23%) reported results for all four schemes (AA, OA, AC, and
MPS), while 49 (33%) participants reported results for only
three schemes (25 for AA, OA, and AC and 23 for AA, OA,
and MPS). Among the 38 (25%) participants reporting results
for two schemes, the most common pair was AA and OA (26
participants) and among the 28 (19%) reporting results for
only one scheme, the most common was AA (22).
AA proficiency testing
The AA challenges included specimens from individuals with
phenylketonuria, maple syrup urine disease, various urea
cycle defects, cystinuria, and other AA transport disorders
(Supplementary Table S1 online). Results from 2013-A were
excluded due to sample degradation likely related to storage.
A total of 141 laboratories (91 US, 50 international) provided
responses, with the number of participants remaining
essentially constant since 2010 at around 95 participants.
Most participants (75% in 2010) used AA analyzers, but this
proportion dropped to 68% in 2014. LC-MS/MS was reported
by three laboratories in 2010 and by nine laboratories in 2014.
AA PT results are summarized in the heat map (Figure 1),
which includes participant-specific performance over time
for both analytic and clinical interpretations (see also
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Supplementary Figure S1). The overall analytic sensitivity
for AA testing was 93.4% (1,552/1,661 responses), with
the highest sensitivities (100%) observed for conditions
related to phenylalanine, citrulline, and arginine metabolism,
and the lowest for abnormalities in β-alanine (87.3%) and
α-aminoadipic acid (86.2%). Stratified by geographic region,
the analytic sensitivity was higher (Po0.001) among US
(95.1%, 1,122/1,180) than among international participants
(89.4%, 430/481). Among US participants, 53 (58%) had no
incorrect responses for analytic sensitivity. Four of these 91
laboratories (4%) accounted for 14 errors (between 3 and 6
each), representing 24% of all analytical errors. Among
international participants, 23 (46%) had no incorrect
responses for analytic sensitivity; six of these 50 laboratories
(12%) accounted for 22 errors (between 3 and 5 each)
representing for 43% of all analytic errors.
The overall clinical sensitivity for all participants was 91.0%
(1,514/1,663), but the clinical sensitivity was significantly
higher among US participants (92.9%; 1,103/1,188) than
international participants (86.5%; 411/475) (Po0.001). Clin-
ical sensitivity was highest for more easily recognizable
conditions (phenylketonuria, 100%) and lowest for combined
homocystinuria/methylmalonic aciduria (2008A, 76.3%).
Despite compelling clinical scenarios, clinical sensitivity was
also lower for several challenges where the differential
diagnosis was broad, including 83.6% for homocystinuria
(2006A, cystathionine-β-synthase deficiency) and 84.0% for
primary lactic acidemia (2008B). Incorrect clinical interpreta-
tions were stratified by incorrect diagnosis (e.g., a sample with
elevated citrulline mistakenly diagnosed as ornithine trans-
carbamylase deficiency rather than citrullinemia) versus
“normal” clinical interpretation. This latter group of false
negatives represented 2.6% (44/1,663) of all interpretations
over the 10-year period. Among US laboratories, the rate of
2.4% (29/1,188) was not different from the 3.2% (15/475)
found among international laboratories (P= 0.41). Since 2010,
however, laboratories have improved with only one false-
negative result occurring in more than 850 distinct clinical
interpretations. A summary of AA performance results along
with 95% confidence intervals is provided in Table 1.
Two challenges with a maple syrup urine disease specimen
were distributed in 2005 and 2011. Leucine quantitation
(Figure 2a) was 18% lower in the later distribution (443 vs.
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Figure 1 Heat maps of CAP proficiency testing results for amino
acid challenges from 2004-B through 2014-B. (a) Heat map for amino
acid proficiency testing for 50 international participants. (b) Heat map for
amino acid proficiency testing for 109 US participants. Each row
represents results from a single laboratory while each column represents
a specific response. Each pair of columns depicts grading results for the
analytic (A) and interpretive (I) component of the challenge (e.g., columns
1 and 2 show analytic and interpretive performance for the B distribution
in 2004). Gray boxes indicate correct responses; black boxes, incorrect
responses; white boxes, no response (or no participation). For clinical
interpretations (I), a white X indicates that the incorrect interpretation
was “Normal, unaffected” (i.e., false-negative result); while a solid black
box indicates that an abnormality was recognized but was incorrect. The
two solid gray columns indicate an ungraded sample (see text).
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541 μmol/l) but the coefficients of variation were comparable
(5.4 vs. 8.9%). Despite the leucine concentration reductions,
results were still significantly elevated and consistent with a
diagnosis of maple syrup urine disease. Among the 60
laboratories participating in both challenges, 57 (95%)
reported results within the 95% prediction interval
(mean± 1.96 standard deviations).
OA proficiency testing
OA challenges included conditions such as MMA and
propionic acidemia along with others (Supplementary
Table S1). A total of 113 laboratories (73 US, 40 interna-
tional) provided responses, with the participation increasing
from 75 in 2010 (53 US, 22 international) to 85 in 2014 (57
US, 28 international). Analytic methods did not change
substantially over the 10-year study period. In 2014, 98% of
participants used gas chromatography/mass spectrometry,
with 94% employing solvent extraction for sample prepara-
tion (50% ethylacetate, 40% ethylacetate/ether, 4% acetonitrile
or other solvents) and 6% using solid-phase extraction. Single
laboratories reported using gas chromatography/mass spec-
trometry or LC-MS/MS methods.
OA performance results are summarized in Tables 1 and 2,
and in a heat map (Supplementary Figure S2). The overall
analytic sensitivity was 92.7% (1,311/1,415), with a higher rate
in US (93.5%; 942/1,007) versus international (90.4%;
369/408) laboratories (P= 0.043). Analytic performance was
excellent for challenges with prominent abnormalities, such
as MMA (2012B, 100%), 5-oxoprolinuria (2009A, 100%), and
fumarase deficiency (2005A, 96.6% and 2011A, 95.0%).
Performance was poor for specimens with modest meta-
bolite elevations, such as MCAD deficiency (2010A, 83.6%
and 2013A, 81.5%). However, the circulation of specimens
originating from different donors with divergent clinical
statuses complicated the investigation of poor performance, as
was the case for MCAD deficiency.
The overall clinical sensitivity was 90.5% (1,301/1,437), and
was significantly higher among US (92.9%; 947/1,019) than
international (84.7%; 354/418) participants (Po0.001). Inter-
pretive performance was excellent for challenges that included
specimens with prominent metabolite elevations and poor for
challenges containing specimens with complex or subtle
findings such as glutaric acidemia type II (2008B, 85.3%) or
isobutyryl-CoA dehydrogenase deficiency (2006B, 75.0%).
Among 73 US participants, 36 (49%) had no interpretive
errors; 29 (40%) had one or two errors, and one laboratory
accounted for nine errors. From 72 total errors, 43 (60%)
reflected an incorrect diagnosis and 29 (40%) were false
negatives (normal diagnosis). Among 40 international
participants, 12 (30%) had no incorrect clinical interpreta-
tions, but two had four errors and one had five errors. In this
group, there were 64 errors, of which 35 (55%) were incorrect
diagnoses but 29 (45%) were identified as normal.
A single OA specimen of fumarase deficiency was
distributed in 2005 and 2011, with quantitative data reported
by 25 and 30 participants, respectively (Figure 2b). Median
fumaric acid concentrations were 451 and 457 mmol/mol
creatinine for the 2005 and 2011 mailings, respectively. The
Table 1 Estimates of analytic sensitivity for the four schemes included in the biochemical genetic laboratories proficiency
testing program stratified by laboratory location
Scheme Location Analytic true positivea Analytic false negativeb P valuec
Amino acids US 95.1% (1,122/1,180)
(93.9–96.3%)
4.9% (58/1,180)
(3.7–6.1%)
o0.001
International 89.4% (430/481)
(86.7–92.2%)
10.6% (51/481)
(7.9–13.3%)
Organic acids US 93.5% (942/1,007)
(92.0–95.1%)
6.5% (65/1,007)
(4.9–8.0%)
0.043
International 90.4% (369/408)
(87.6–93.3%)
9.6% (39/408)
(6.7–12.4%)
Acylcarnitine profile US 93.1% (471/506)
(90.9–95.3%)
6.9% (35/506)
(4.7–9.1%)
0.060
International 88.9% (192/216)
(84.7–93.1%)
11.1% (24/216)
(6.9–15.3%)
Mucopolysaccharides US
(Screening)
93.0% (318/342)
(90.3–95.7%)
7.0% (24/342)
(4.3–9.7%)
0.056
International
(Screening)
88.2% (179/203)
(83.7–92.6%)
11.8% (24/203)
(7.4–16.3%)
US
(Fractionation)
91.4% (213/233)
(87.8–95.0%)
8.6% (20/233)
(5.0–12.2%)
0.0010
International
(Fractionation)
79.0% (94/119)
(71.7–86.3%)
21.0% (25/119)
(13.7–28.3%)
aProportion of correct abnormal analyte identified (analytic sensitivity). bProportion of incorrect abnormal analyte identified, or no abnormal analyte identified. cCompar-
ison of analytic sensitivity between US and international participants.
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results indicate satisfactory agreement between participants
reporting quantitative values. There were a handful of outliers,
yet their results were still indicative of fumarase deficiency.
AC proficiency testing
AC challenges included disorders of fatty acid oxidation such
as MCAD deficiency, very long-chain acyl-CoA dehydrogen-
ase deficiency, and long-chain hydroxyacyl-CoA dehydrogen-
ase deficiency, as well as primary carnitine transporter defi-
ciency, and organic acidemias such as MMA and propionic
acidemia (Supplementary Table S1). A total of 65 labora-
tories (42 US, 23 international) provided results, with the
number of participants rising from 43 in 2010 to 52 in 2014.
By 2014, all laboratories were using (LC-MS/MS) with 91%
utilizing butyl esters and the remainder using methyl esters or
underivatized compounds.
AC performance results are summarized in Tables 1 and 2
and in a heat map (Supplementary Figure S3). The
overall analytic sensitivity was 91.8% (663/722), with 93.1%
(471/506) in US laboratories and 88.9% (192/216) in interna-
tional laboratories (P= 0.083). Analytic sensitivity was 100% for
several challenges including MCAD, MMA/propionic acidemia,
and a recent very long-chain acyl-CoA dehydrogenase deficiency
challenge (2014A). The lowest analytic sensitivity (64.5%) was
seen for the 2009A challenge of long-chain hydroxyacyl-CoA
dehydrogenase deficiency. Among all 65 participants, 29 (45%)
had no analytical errors. One or two errors were made by 19
(29%) and 12 (18%) participants, respectively. Five laboratories
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Figure 2 Comparisons of reported analyte quantitation from identical sample challenges provided in different years. (a) The reported
leucine quantitation from the same maple syrup urine disease sample tested in 2005 (n= 93) and 2011 (n= 95). Lines represent the median (solid) and
± 3 s.d. (dotted) values of participant responses for each year, with the darker gray box indicating acceptable performance. Sixty participants responded
to both surveys. Open circles indicate the results falling within the computed prediction limits while dark circles are those results outside those limits for
one or both distributions. Open circles just to the left of the y-axis or just above the x-axis represent results from laboratories reporting only in 2005 or
2011, respectively. An arrow next to an observation indicates the reported value is higher (or lower) than the range depicted. (b) Fumarate quantitation
from the same fumarase deficiency sample tested in 2005 (25 responses) and in 2011 (29 responses); 16 participants responded to both surveys. Lines,
symbols, and shading are the same as for (a). (c) Glutarylcarnitine quantitation from the same specimen submitted in both 2008 (15 responses) and
2012 (35 responses). There were insufficient data to compute prediction limits for 2008. Lines, symbols, and shading are the same as for (a). An arrow
next to an observation indicates the reported value is higher (or lower) than the range depicted. (d). Malonylcarnitine quantitation from the same
specimen submitted in both 2008 (26 responses) and 2012 (33 responses). Although individual laboratories tended to provide similar results for both
challenges, those results differed significantly between laboratories. Thus, the prediction limits fall around a line rather than a point. Lines, symbols, and
shading are the same as for (a).
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(three US and two international, or 8%) reported three or more
errors, and these participants accounted for 16 of the 59 total
analytic errors (27%).
The overall clinical sensitivity for AC PT was 88.0%
(650/739), but this rate was higher among US laboratories
(90.1%; 462/513) compared to international laboratories
(83.2%; 188/226) (P= 0.010). For three challenges (2005B,
2006A, and 2014A), all laboratories identified the correct
abnormal analyte(s) (100% analytic sensitivity) and also
provided the correct clinical interpretation (100% clinical
sensitivity). Challenges with lower clinical sensitivities either
had nonspecific analytic findings compatible with more than
one disorder (e.g., elevated C5OH in β-ketothiolase deficiency
(77.5%); low free carnitine in carnitine uptake defect (75.7%)),
or had only modest analyte elevations, including both
challenges containing specimens from known patients with
long-chain hydroxyacyl-CoA dehydrogenase deficiency
(75.0% and 74.4%). Among the 65 participants, 23 (35%)
had no interpretive errors during the 10-year period and 31
(48%) had one or two errors. Eleven laboratories (17%) had
three or more errors; one with five and two with six. Among
these 89 errors, a subset reported that there was no disorder
identified; a false-negative result. The rates for this type
of error differed significantly by location (P= 0.001), with a
2.7% (14/513) and 8.0% (18/226) difference in the US and
international participants, respectively (Table 2).
Among challenges constituting a specimen submitted for
PT more than once, and for which results included quanti-
tative AC values, concentrations for significant AC results are
shown in Figure 2c,d. Broad interlaboratory variation was
observed for glutarylcarnitine (C5DC) in 2005 (four results
> 300 nmol/ml and 10 between 1 and 5 nmol/ml), with
significant improvement in 2010 (one result of 189 nmol/ml
and 32 between 1 and 5 nmol/ml). Interlaboratory variability
was also observed for malonylcarnitine (C3DC) measure-
ments obtained from a specimen submitted for challenges in
2008 and 2012 (Figure 2d). While there was high inter-
laboratory variability in both 2008 and 2012, one outlier was
identified among the 19 laboratories participating in both
challenges. The remaining results were highly correlated
(N= 18, r= 0.84), indicating low intralaboratory variability
and the need for further standardization efforts.
MPS proficiency testing
MPS challenges included Hurler/Hunter (MPS-I/II, graded
together), Sanfilippo (MPS-III), Morquio (MPS-IV), and Sly
(MPS-VII) syndromes, as well as six normal individuals
(Supplementary Table S1). Results were reported for a
screening assay for total MPS and/or a fractionation assay
(elevations of keratan sulfate, dermatan sulfate, heparan
sulfate, and chondroitin sulfate). Overall, 72 laboratories
(42 US and 30 international) participated in the PT.
Dimethylmethylene blue binding assay (50%) was the most
common screening method, followed by toluidine blue (16%),
Berry spot test (11%), and Alcian blue spot test (5%). Thin-
layer chromatography and electrophoresis were reported
among fractionation methods in similar frequencies, but
LC-MS/MS increased to 11% by 2014.
MPS performance is summarized in Tables 1 and 2 and
in a heat map (Supplementary Figure S1). Two MPS-VII
samples (2008A, 2011A) were excluded from analysis due
to the lack of participant consensus (o80%). The com-
bined analytic sensitivity for all screening methods was
91.2% (497/545) with similar (P= 0.060) performance by US
Table 2 Estimates of clinical sensitivity for the four schemes included in the biochemical genetic laboratories proficiency
testing program stratified by laboratory location, along with the rate of the two types of false-negative errors
True positive False negative
Schemes Location Correct diagnosisa Incorrect disorder identifiedb No disorder found: normalc P valued
Amino acids US 92.9% (1,103/1,188)
(91.4–94.3%)
4.7% (56/1,188)
(3.5–5.9%)
2.4% (29/1,188)e
(1.6–3.3%)
o0.001
International 86.5% (411/475)
(83.5–89.6%)
10.3% (49/475)
(7.6–13.1%)
3.2% (15/475)
(1.6–4.7%)
Organic acids US 92.9% (947/1019)
(91.4–94.5%)
4.2% (43/1019)
(3.0–5.5%)
2.9% (29/1019)
(1.8–3.9%)
o0.001
International 84.7% (354/418)
(81.2–88.2%)
8.4% (35/418)
(5.7–11.0%)
6.9% (29/418)
(4.5–9.4%)
Acylcarnitine profile US 90.1% (462/513)
(87.5–92.7%)
7.2% (37/513)
(5.0–9.5%)
2.7% (14/513)
(1.3–4.1%)
0.0082
International 83.2% (188/226)
(78.3–88.1%)
8.8% (20/226)
(5.1–12.6%)
8.0% (18/226)
(4.4–11.5%)
Mucopolysaccharides US 88.3% (227/257)
(84.4–92.3%)
8.9% (23/257)
(5.5–12.4%)
2.7% (7/257)
(0.7–4.7%)
o0.001
International 72.1% (106/147)
(64.69–79.4%)
20.4% (30/147)
(13.9–26.9%)
7.5% (11/147)
(3.2–11.7%)
aProportion of participants correctly identifying the targeted disorder (clinical sensitivity). bProportion of participants incorrectly identifying a disorder other than the inten-
ded target. cProportion of participants incorrectly providing a normal response for a challenge with a specific disorder. dComparison of clinical sensitivity between US and
international participants. eAll false-negative results occurred prior to 2011.
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(93.0%, 318/342) and international participants (88.2%,
179/203). Screening performance was best for MPS-I/II
(analytic sensitivity 96.5%; 164/170), but poorer for MPS-III
(88.1%; 185/210). Analytic sensitivity for the fractionation
assays was 87.2% (307/352) and performance was significantly
higher (P= 0.001) for US (91.4%, 213/233) than for interna-
tional (79.0%, 94/119) participants. The sensitivity of
fractionation assays was highest for MPS-III (95.7%; 132/138)
and lowest for MPS-IV (78.8%; 63/80). Screening assays were
more sensitive than fractionation methods for detecting an
MPS abnormality. In particular, discrepancies were noted
between the screening and fractionation methods for the
2010A challenge of MPS-II (100 vs. 83%) and the 2010B
challenge of MPS-IV (98 vs. 73%)
The overall clinical sensitivity was 82.4% (333/404), with a
significant difference (Po0.001) between US (88.3%, 227-
/257) and international (72.1%, 106/147) laboratories. Clinical
sensitivity was highest among MPS-III (Sanfilippo syndrome)
challenges (88.2%; 135/153). The MPS-VII (Sly syndrome)
challenges were the most problematic; two PT challenges
lacked consensus for grading and the third had an overall
clinical sensitivity of 79.3% (23/29).
For screening assays, 86% of laboratories (62/72) made one
or fewer analytical errors (56% had no errors, 31% had one
error). In addition, 10 laboratories (14%) made two or more
errors apiece and were responsible for 26 of the 48 errors
(54%). For the 49 laboratories utilizing fractionation assays,
33% (16) had no errors and 51% (25) had one error. The
remaining eight laboratories (16%) made two or more errors
apiece and were responsible for 20 of 45 errors (44%). Of the
56 laboratories reporting interpretations, 70% (39/56) had
none or one interpretative error. The remaining 17 (30%)
laboratories with two or more errors were responsible for 70%
(50 /71) of the errors.
Analytic specificity, calculated from results of the six
normal samples, was 99.6% (254/255) for the screening assay
and 93.9% (139/148) for the fractionation assay. Stratifying
fractionation results by laboratory location revealed an
analytic specificity of 96.1% (99/103) among US and 88.9%
(40/45) among international participants (P= 0.091). Overall,
85% (23/27) of US and 79% (15/19) of international
laboratories had no analytic specificity errors. The corre-
sponding clinical specificity was 89.0% (169/190) with no
significant difference by laboratory location.
DISCUSSION
The vast majority of PT participants accurately identified
diagnostic abnormalities and correctly interpreted corre-
sponding genetic conditions. Performance was excellent for
challenges with prominent and characteristic biochemical
abnormalities, including samples from patients with classic
genetic conditions such as phenylketonuria, MMA, and very
long-chain acyl-CoA dehydrogenase deficiency. In contrast,
performance waned when challenges involved more subtle
analytical findings (e.g., minimally elevated C16-OH AC
concentrations seen in long-chain hydroxyacyl-CoA
dehydrogenase deficiency), diagnoses relying on the recogni-
tion of a complex, multianalyte pattern (e.g., multiple acyl-Co
dehydrogenase deficiency) and ultrarare conditions (e.g.,
mevalonic aciduria). Importantly, the proportion of partici-
pants completely missing a definitive diagnosis was low, and
the majority of conditions were recognized as having
abnormal biochemical profiles, even if the precise diagnosis
provided was deemed unacceptable in the PT scheme.
Among the selected laboratories, performance over this study
period was steadily higher among US laboratories than
international laboratories. The reason for this tendency is
unknown. Several factors between laboratories may account for
this correlation. In particular, there exist specialized US
laboratories (Clinical Biochemical Genetic Laboratories)
devoted to the diagnosis and management of IEMs, and the
United States has accredited training for clinical biochemical
genetic laboratory directors, overseen by the American Board of
Medical Genetics and Genomics, that aims to ensure excellence
among laboratory directors through continuing education,
among other activities. International laboratories may not have
access to accredited training programs. Additionally, the
distribution of PT specimens may face sporadic delays
occurring during shipment to distant destinations thereby
affecting sample integrity and impacting interpretation. Indeed,
participating laboratories are requested to ensure that speci-
mens arrive frozen and within their storage requirements.
Nevertheless, adherence to this request relies on self-reported
observations that may be hindered by storage, unpacking, and
repackaging at custom office locations. Finally, rare disease
incidence differences among populations worldwide may lead
to the occurrence that a common genetic condition in one part
of the world is seldom observed, if at all, in another region.
Hence, laboratories can have divergent experiences with the full
spectrum of IEMs. Thus, difference in performance may be due
to a combination of these or other factors.
Because multiple factors probably contributed to perfor-
mance variance for both US and international laboratories, a
central function of PT is to prompt assay troubleshooting,
process refinement, and quality improvement when failures
do occur. This includes prompting laboratories to review their
processes for analyte extraction and derivatization, method
calibration, and instrument optimization. Analytic errors may
also reflect limitations in available laboratory methods, such
as for MPS screening and fractionation where assay short-
comings are well recognized18 and addressed by emerging
new LC-MS/MS methods.19,20 Some errors may result from
constraints inherent to the PT process itself, where lower
estimates of clinical sensitivity may be due to the lack of
supporting clinical information or results of other laboratory
tests. This underscores the importance of clinical history
when interpreting analytic findings, as pointed out by other
groups.21 Finally, because laboratories submit PT results
outside of their normal data transmission and reporting
protocols, inadvertent clerical errors may also occur.
Incorrect interpretations also may have resulted from the
strict requirement to report a specific diagnosis, even in cases
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for which additional testing may be warranted in actual
practice. For example, a suspected case of MCAD deficiency
identified by OA analysis typically requires additional
confirmation by AC analysis, and positive MPS screening
and fractionation results requires confirmation by enzyme
and/or DNA testing.21 Responses representing an incorrect
diagnosis (as opposed to a “normal” response in the face of a
true abnormality) were classified as false-negative results for
this report. Although considered a PT failure, in practice an
incorrect diagnosis still is likely to be followed by repeat
testing, additional studies, or gathering of additional clinical
or family history. Indeed, some diagnoses included in PT
schemes, such as carnitine uptake defect (an AC challenge) or
glycine encephalopathy (a plasma AA challenge), may have
been particularly challenging since these conditions are more
appropriately diagnosed in conjunction with other tests (free
and total carnitine and cerebrospinal fluid AA analysis,
respectively). Nonetheless, despite the inherent constraints of
PT, a correct diagnosis could most often unequivocally be
assigned based on results of a single test.
Among other PT programs available for BGLs, the European
consortium ERNDIM provides challenges for qualitative OA
and urine MPS schemes that are similar to the CAP/ACMG
program. As a comparison, reported ERNDIM performance (see
http://www.erndim.org/home) for 2015 showed that accuracy
ranges from 60 to 89% for MPS and 85 to 100% for OA. Hence,
the PT performance of laboratories observed in the CAP/ACMG
scheme is similar to those found in other programs.
From this study, current clinical biochemical genetic labora-
tories demonstrated good overall performance on PT. Remain-
ing challenges for laboratories include the need for standardizing
laboratory methods and reagents, and ensuring that ongoing
education enhances the awareness of genetic disorders, and their
diagnostic profiles, thereby benefiting patient care.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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